In addition, the modulation of the dopaminergic system and the ability to reduce ventral tegmental area (VTA) firing and dopaminergic release led to experimenting with TAAR1 agonists as a potential treatment in schizophrenia and psychotic disorders [31]. Here, TAAR1 is linked to schizophrenia.